People with sensitive skin usually have a hard time finding the right treatment for themselves. Harsh ingredients used in many of the most popular and most efficient facials are often unsuitable for this skin type. The sensiglow treatment, however, is specially tailored for sensitive skin
As per the Ayurveda, paralysis treatment includes a balance of herbal medications, Ayurvedic massages, and lifestyle changes. We at Parijatak incorporate the same at each stage of our paralysis treatment in Ayurveda to ensure effective outcomes and quick recovery. Under the expertise of several therapists, we work out the best initiatives to give paralysis Ayurvedic cure a completely new form.
The Pharmacists' Defence Association (PDA) has issued an advisory information to community pharmacy contractors about Paxlovid antiviral treatment for
non-hospitalised patients.
"Patients will be assessed to see if they meet the criteria for inclusion and will need careful checking to see if Paxlovid therapy is safe due to the significant
number of drug interactions. Assessment and prescribing are provided via dedicated services with dispensing and supply arranged by the central supply service or
via participating community pharmacies," said the PDA.
Every pharmacist can support this service by making themselves familiar with the service set up in their area. This is so that they can provide advice and signpost
to healthcare colleagues and patients.
Pharmacists working in general practice may also be able to help with identifying newly diagnosed highest risk patients. Whilst most of this group should have
already been identified and contacted, no system is entirely foolproof.
The PDA's advisory note provides information around indemnity and links to information about the prescribing and administration of Paxlovid since it is being
provided under a temporary authorisation, and is subject to numerous drug-drug interactions, and is a recommended first-line treatment.
'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced
non-small-cell lung cancer (NSCLC).
The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project
Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster.
NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating
advanced NSCLC with METex14 skipping gene alterations in adults.
People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England.
Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700
people in England would be eligible to receive tepotinib as either a first or second-line treatment.
National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft
guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise.
The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate
glucose control when using current treatment options.
Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with
semaglutide or insulin therapy.
The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were
observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain.
The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative
treatments.
Bipolar disorder can be a very challenging mental illness to deal with. It is characterized by severe mood swings, from manic highs to depressive lows. Many
people with bipolar disorder struggle to live normal, productive lives. However, there are various treatments available that can help manage the symptoms of this
condition and improve quality of life. In this article, we will discuss the different treatments for bipolar disorder and how to properly deal with the symptoms.
MEDICATIONS
One of the most common treatments for bipolar disorder is medication. There are a variety of different medications that can be used to treat the symptoms of bipolar
disorder. The type of medication that is prescribed will depend on the individual's specific situation. Some common medications that are used to treat bipolar
disorder include mood stabilizers, antipsychotics, and antidepressants. However, it is important to note that these are serious medications and should only be taken
under the supervision of a qualified mental health professional. So, never attempt to take these medications on your own.
The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration
or diabetic macular oedema.
Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment.
Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with
diabetic macular oedema (DMO).
In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective.
Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.
UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir.
The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection.
Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection.
A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent.
It further revealed that Paxlovid is most effective when taken in the early stage of infection.
Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered
intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."
In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a
new Johnson & Johnson drug in Britain.
Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to
six months of symptom control and a reduction in their risk of relapse with only two doses a year.
It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous
absorption of paliperidone palmitate over a six-month period.
"Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness
experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.
The new deal struck by the NHS will enable provision of a life-saving treatment for babies and young children who suffer with a rare and fatal genetic disease, metachromatic leukodystrophy (MLD).
The revolutionary gene therapy treatment, known by its brand name Libmeldy, is used to treat MLD, which causes severe damage to the child's nervous system and organs,
leading to a life expectancy of just five to eight years.
Having a reported list price of more than £2.8 million, it is the most expensive drug in the world, but can now be offered to young patients on the NHS in England after the health service negotiated a significant confidential discount.
the drug works by removing the patient's stem cells and replacing the faulty gene that causes MLD before then re-injecting the treated cells into the patient.
The most common form of MLD usually develops in babies younger than 30 months and can cause loss of sight, speech and hearing, as well as difficulty moving, brain impairment, seizures, and eventually death.
The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin.
It's final draft guidance is expected to be available on the July 20.
Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with
controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides.
NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo.
Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.
The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available
to purchase potentially life-saving drugs early.
This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments
Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or
save their lives.
"The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people
renewed hope for a better future."
A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients.
DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with
few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to
the smaller patient cohort.
AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with
advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free
survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with
chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial,
said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for
the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community."
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an
unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour
BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary
endpoints as well as data for relevant subgroups."
Good news for patients whose epilepsy cannot be controlled by standard anti-seizure drugs! Next month, NHS England will introduce a cutting-edge laser beam
therapy that can prevent seizures in these individuals.
Known as Laser Interstitial Thermal Therapy (LITT), the advanced treatment targets the part of the brain causing seizures without the need for invasive surgery,
the health service said.
The new fibre optic laser therapy is being offered at King's College Hospital in London and The Walton Centre in Liverpool. Starting from June, it will be gradually
extended to eligible patients across England.
Each year, it is expected to benefit up to 50 epilepsy patients in England who are resistant to standard anti-seizure medications.
"This groundbreaking new treatment will change the lives of those with severe epilepsy improving quality of life and providing much-needed assurance," said Andrew
Stephenson, Minister of State for Health.
Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical
trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer.
The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers
at Imperial College London.
For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research
Facility at Hammersmith Hospital.
In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of
immune checkpoint inhibitor.
The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for
difficult-to-treat cancers.
In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions.
The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From
non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns.
This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also
how we feel about ourselves.
Botox Injections
Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial
muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the
forehead, crow's feet, and frown lines between the brows.
The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com
note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine
lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.
Great news for multiple sclerosis patients! The NHS has introduced a new 10-minute injection that can slow the progression of disability while reducing
hospital treatment time by over 90 per cent.
Currently, MS patients in England receive ocrelizumab (Ocrevus), manufactured by Roche, through twice-yearly intravenous (IV) infusions that can last up to
four hours.
Now, around 9,000 NHS patients in England will be able to receive the drug via a quick 'under-the-skin' twice-yearly injection. It takes just ten minutes,
enabling patients to spend less time in the hospital receiving treatment.
This roll-out follows approval from the Medicines and Healthcare products Regulatory Agency (MHRA), making the NHS one of the first healthcare systems
worldwide to offer this new MS injection. Drug stocks are expected to be available in the coming weeks.
Indian pharmaceutical companies are gearing up to become global suppliers of repurposed Covid-19 drugs.
With the launch of new innovative Covid-19 oral drugs, Indian companies are again expected to grab opportunities in the global supply of oral Covid-19 drugs, according to data and analytics company GlobalData.
As several countries witness increasing cases of Covid-19 despite vaccination, they have started booking supply orders for innovative Covid-19 treatments like antibody cocktails, monoclonal antibodies and the latest addition such Merck's the oral Covid-19 drug 'molnupiravir'.
Prashant Khadayate, pharma analyst at GlobalData, comments: "Oral treatment for Covid-19 would be the most convenient option for the patients ranging from mild
to moderate Covid-19 and would not require a hospital setting. Currently, a majority of the Covid-19 treatments require a hospital setting."
According to GlobalData's Pharma Intelligence Center, the UK is the first country to approve molnupiravir which is in pre-registration stage in the US, EU and Japan.
Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, a recent study has revealed.
The research has been published in the 'British Journal of Psychiatry Open'.
A systematic review led by the University of Exeter and funded by the Medical Research Council analysed evidence from 83 published research papers. The strongest
evidence emerged around the use of ketamine to treat both major depression and bipolar depression.
Symptoms were reduced as swiftly as one to four hours after a single treatment and lasted up to two weeks. Some evidence suggested that repeated treatment may
prolong the effects, however more high-quality research is needed to determine by how long.
Similarly, single or multiple doses of ketamine resulted in moderate to large reductions in suicidal thoughts. This improvement was seen as early as four hours following ketamine treatment and lasted on average three days, and up to a week.